Suppr超能文献

受体酪氨酸激酶抑制剂在癌症中的应用。

Receptor tyrosine kinase inhibitors in cancer.

机构信息

Genetics Division, Department of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Iran.

Medical Branch, Islamic Azad University of Tehran, Tehran, Iran.

出版信息

Cell Mol Life Sci. 2023 Mar 22;80(4):104. doi: 10.1007/s00018-023-04729-4.

Abstract

Targeted therapy is a new cancer treatment approach, involving drugs that particularly target specific proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are involved in promoting growth and proliferation, Therefore inhibiting these proteins could impede cancer progression. An understanding of RTKs and the relevant signaling cascades, has enabled the development of many targeted drug therapies employing RTK inhibitors (RTKIs) some of which have entered clinical application. Here we discuss RTK structures, activation mechanisms and functions. Moreover, we cover the potential effects of combination drug therapy (including chemotherapy or immunotherapy agents with one RTKI or multiple RTKIs) especially for drug resistant cancers.

摘要

靶向治疗是一种新的癌症治疗方法,涉及专门针对癌细胞中特定蛋白质的药物,例如受体酪氨酸激酶(RTKs),它们参与促进生长和增殖,因此抑制这些蛋白质可能会阻碍癌症的进展。对 RTKs 和相关信号级联的理解,使许多使用 RTK 抑制剂(RTKI)的靶向药物治疗得以发展,其中一些已经进入临床应用。在这里,我们讨论 RTK 的结构、激活机制和功能。此外,我们还介绍了联合药物治疗(包括一种 RTKI 或多种 RTKIs 与化疗或免疫治疗药物联合使用)的潜在影响,特别是针对耐药性癌症。

相似文献

1
Receptor tyrosine kinase inhibitors in cancer.
Cell Mol Life Sci. 2023 Mar 22;80(4):104. doi: 10.1007/s00018-023-04729-4.
2
Receptor Tyrosine Kinase Phosphorylation Pattern-Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment.
Mol Cancer Ther. 2016 Oct;15(10):2508-2520. doi: 10.1158/1535-7163.MCT-15-0735. Epub 2016 Jul 25.
4
Acquired resistance to drugs targeting receptor tyrosine kinases.
Biochem Pharmacol. 2012 Apr 15;83(8):1041-8. doi: 10.1016/j.bcp.2011.12.025. Epub 2011 Dec 26.
5
Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
Mol Cancer Ther. 2016 Dec;15(12):3028-3039. doi: 10.1158/1535-7163.MCT-16-0366. Epub 2016 Sep 16.
6
Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.
J Med Chem. 2021 May 27;64(10):6566-6568. doi: 10.1021/acs.jmedchem.1c00698. Epub 2021 May 7.
7
Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Int J Mol Sci. 2018 Nov 6;19(11):3491. doi: 10.3390/ijms19113491.
8
9
Mechanisms of receptor tyrosine kinase activation in cancer.
Mol Cancer. 2018 Feb 19;17(1):58. doi: 10.1186/s12943-018-0782-4.
10
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Semin Oncol. 2006 Aug;33(4):407-20. doi: 10.1053/j.seminoncol.2006.04.005.

引用本文的文献

4
Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications.
Research (Wash D C). 2025 Jun 21;8:0747. doi: 10.34133/research.0747. eCollection 2025.
8
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs.
J Hematol Oncol. 2025 May 1;18(1):52. doi: 10.1186/s13045-025-01703-4.
9
MicroRNAs as Sensitizers of Tyrosine Kinase Inhibitor Resistance in Cancer: Small Molecule Partnerships.
Pharmaceuticals (Basel). 2025 Mar 28;18(4):492. doi: 10.3390/ph18040492.
10
Impact of Tyrosine Kinase Inhibitors on the Expression Pattern of Epigenetic Regulators.
Cancers (Basel). 2025 Apr 10;17(8):1282. doi: 10.3390/cancers17081282.

本文引用的文献

2
Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial.
Front Oncol. 2022 May 26;12:811687. doi: 10.3389/fonc.2022.811687. eCollection 2022.
3
Neurotrophic tyrosine receptor kinase fusion in pediatric central nervous system tumors.
Cancer Genet. 2022 Apr;262-263:64-70. doi: 10.1016/j.cancergen.2022.01.003. Epub 2022 Jan 19.
4
5
Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability.
Antibodies (Basel). 2022 Jan 13;11(1):6. doi: 10.3390/antib11010006.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验